ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

USA Baillie Gifford Us Growth Trust Plc

162.40
0.00 (0.0%)
30 Nov 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Baillie Gifford Us Growth Trust Plc LSE:USA London Ordinary Share GB00BDFGHW41 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 162.40 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
162.00 162.60
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -9.32M -15.59M -0.0511 -31.82 496.18M
Last Trade Time Trade Type Trade Size Trade Price Currency
17:45:23 O 6,076 162.00 GBX

Baillie Gifford Us Growth (USA) Latest News

Baillie Gifford Us Growth (USA) Discussions and Chat

Baillie Gifford Us Growth Forums and Chat

Date Time Title Posts
17/10/202313:43Baillie Gifford US Growth Trust173
26/3/201812:09Baillie Gifford US Growth1
26/2/201618:33test2-
26/2/201618:33test-
29/7/201308:28Trading in US Shares12

Add a New Thread

Baillie Gifford Us Growth (USA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:15:05162.006,0769,843.12O
2023-11-29 16:56:43162.10250,000405,250.00O
2023-11-29 16:35:00162.4025,62641,616.62UT
2023-11-29 16:30:09161.2050,00080,600.00O
2023-11-29 16:26:47162.585,0008,128.90O

Baillie Gifford Us Growth (USA) Top Chat Posts

Top Posts
Posted at 29/11/2023 08:20 by Baillie Gifford Us Growth Daily Update
Baillie Gifford Us Growth Trust Plc is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker USA. The last closing price for Baillie Gifford Us Growth was 162.40p.
Baillie Gifford Us Growth currently has 305,153,700 shares in issue. The market capitalisation of Baillie Gifford Us Growth is £496,179,916.
Baillie Gifford Us Growth has a price to earnings ratio (PE ratio) of -31.82.
This morning USA shares opened at -
Posted at 23/8/2023 09:26 by vacendak
Basically someone has read the AR and is putting the highlights in this article.

I am torn between topping up on some unloved PE trust or USA... I think I will top-up on NBPE again, at least they give a divi.
Posted at 17/6/2023 05:31 by takeiteasy
Owning a share like this trust with a high PE element has been like watching paint dry for the recent lack of excitement compared to the earlier days pre COVID...but who knows our patience may be rewarded eventually with a chance that the valuations may start to be influenced by firms wanting to go public again and be rewarded with the appropriate valuation...



The IPO schedule has been remarkably quiet over the past 18 months as appetite for new issuances sank with the overall market prices. The few companies that have gone public have mostly been small, interesting micro caps.

Cava is the first high-profile IPO since 2021, when every week seemed to have a SPAC (special purpose acquisition company) merger or IPO lead the headlines. The heavy demand for CAVA shares seen on Thursday means that investment banks will likely get to work in order to bring the next batch of private companies to public markets.

Halfway through 2023, there have only been about 45 IPOs on Wall Street, which have raised a collective $7.6 billion. This is already nearly overtaking the value of IPOs in all of 2022 but is not even close to 2021’s exuberant IPO market. In that year Wall Street pushed out nearly 400 IPOs that raised more than $142 billion in capital.

dyor etc
Posted at 01/6/2023 12:20 by vacendak
I guess those "growth only/no dividend" funds are at the mercy of the interest rate saga. When things calm down a bit, maybe after a short recession to dampen inflation, things should go back to normal, this time without the extravagance of yesteryear.

The PE ITs I invest in at the moment NBPE and CTPE pay a dividend, so even with the silly discount, I get something for sitting tight. Still mildly optimistic about USA but not as mad about it as I used to be. :(
Posted at 01/6/2023 12:00 by takeiteasy
Interesting views - what do you make of the pure BG USA VC fund and I won't write down the fullname in case I wrongly type it but starts with an S...it seems to have a larger discount too..
Posted at 01/6/2023 11:57 by vacendak
At least this one is with a country that should still be open for business in the future.

I got burnt badly with BGCG (China Trust) with the same remit: Pure growth/Tomorrow's companies. I exited towards the end of 2022, not so unlucky me this time as it is doing even worse now.

Still holding on USA, not crystalising my losses. I am considering adding a bit more at some point. I am currently piling into PE where the discounts are also too wide.
Posted at 21/5/2022 10:00 by vacendak
The thing about Tesla is the same as for Google.
Google is not a search engine, it is a data slurper.

Likewise, Tesla is a data slurper/AI developer that happens to sell a car on the side for collecting that data.

I am pretty sure that most of the tech companies are also not valued on what they do/sell primarily, but what they do, or will be able to do, behind the scenes. Hence the high volatility.

Anyway, USA will likely rise again.
Posted at 20/5/2022 15:41 by spectoacc
Trashed in trash.

Got eye on BG funds - SMT, USA, BGEU - but none seem like buys yet.

Epoch-defining bubble, why not an epoch-defining bust. MoneyWeek suggests we're a year away from the bottom (but who knows).

Other problems are BG's recent fondness for unlisteds - fine, when money is free and no-profit, minimal-revenue Unicorns are everywhere. Not so good when the market turns, and revaluations (down) take so long to come through. SMT's NAV clearly isn't likely to be what's currently reported, with c.30% in unlisteds.


USA Top 10 according to April Factsheet:

TSLA (still multiples over-valued)
The Trade Desk (no idea)
Space Exploration Technologies (ditto)
Stripe
Moderna
Amazon
Faire Wholesale (no idea)
Brex (no idea)
Shopify (cheaper than it was! 77% down in 6 months, 9% just today)
Illumina


BG really like Moderna, Ilumina, TSLA, seem to be in almost every fund.

Don't follow a few of those holdings - opinions welcome.

Discount getting near highs, and there's been a few buy-backs, but another big problem with BG ITs - they're sufficiently gung-ho to have gone into the tech crash with gearing, and that gearing rises the further their holdings fall.
Posted at 20/4/2022 22:40 by 29palms
Tesla reports $18.76 billion in revenue and record margins in Q1

:Tesla beat analysts’ expectations on top and bottom lines for Q1 2022
:For the period ending March 31, 2022 Tesla reported $3.22 earnings per share, and revenue of $18.76 billion
:It also recorded record automotive margins of 32.9%

:Earnings per share: $3.22 vs $2.26 expected
:Revenue: $18.76 billion vs $17.80 billion expected

Shares rose as high as 6% in after-hours trading
Posted at 16/11/2020 23:39 by joy division still
Well I held off...... and missed out, but in today with a decent chunk. Mind u it still looks to high, but it's the only sector I'm not in. Really not sure which of these USA ITs are best, SMT, PCT, ATT but I've probably gone for the worst future performance!
Posted at 18/5/2020 17:04 by whitestone
The funds behind the US stock lifting Covid-19 vaccine hopes

By Daniel Grote 18 May, 2020 at 16:18

The funds behind the US stock lifting Covid-19 vaccine hopes
Baillie Gifford is among the major backers of Moderna (MRNA.O), the US biotechnology company which has sent stock markets rallying with news of a promising early trial for its experimental Covid-19 vaccine.

Shares in Moderna have surged 25% after the company reported promising results from an early study of the vaccine conducted by the US National Institutes of Health. Eight patients who were administered the vaccine were found to have antibody levels similar to those that have recovered from the coronavirus.

‘We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from Sars-CoV-2,’ said St√©phanie Bancel, Moderna chief executive.

Global stock markets were also lifted by the news, on hopes a medical breakthrough in the fight against the coronavirus pandemic could allow locked-down economies to reopen more quickly. The FTSE 100 was up 3.3% at 5,993 while in the US, the S&P 500 opened 2.5% higher.

Growth-focused Edinburgh fund group Baillie Gifford is among the major backers of Moderna, holding just under 1% of the shares in a stake worth $284m, according to Refinitiv data. Moderna shares have soared 338% since the turn of the year on investor hopes over the progress of its coronavirus vaccine.

The fund group’s two best-performing funds of the last three years hold the stock. The £3.5bn Baillie Gifford American fund, up 117.7% over the last 36 months, has an $83.8bn stake, according to Refinitiv data accounting for around 2% of the portfolio.

The £405m Baillie Gifford Positive Change fund, the best-performing fund in the Investment Association’s Global sector over the last three years, also holds the shares. It holds a $19.4m position according to Refintiv, accounting for around 3.8% of the portfolio.

Shares in the £483m Baillie Gifford US Growth (USA) investment trust were up 3.8% at 193p today, thanks in part to its $9.4m position in Moderna shares.

BB Biotech (BION.AS) was meanwhile up 4.5% at 66.75 CHF, boosted by the £3bn Swiss investment company’s 4% portfolio stake in the stock according to the latest factsheet.

BB Biotech and Baillie Gifford were early backers of Moderna, with Baillie Gifford having invested in the stock at its flotation in December 2018. Linden Thomson, manager of the £468m AXA Framlington Biotech fund, is a more recent convert, having bought the shares in March.

‘We initiated a position in Moderna Therapeutics, which has one of the most advanced programmes to develop a vaccine against Covid-19,’ she said in her most recent update to investors. Refinitiv data shows she has built a position worth $11.9m, or around 2% of her fund.

Two exchange-traded funds have significant positions in the shares. The £102m iShares Nasdaq US Biotechnology Ucits ETF, up 2.7% today, has a 2% portfolio position according to its latest factsheet, while the $18.6m L&G Healthcare Breakthrough Ucits ETF has a 1.1% position, according to Refinitiv.
Baillie Gifford Us Growth share price data is direct from the London Stock Exchange

Your Recent History

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com